Free Trial
OTCMKTS:APLIF

Appili Therapeutics (APLIF) Stock Price, News & Analysis

Appili Therapeutics logo
$0.01 +0.00 (+14.75%)
As of 01:58 PM Eastern

About Appili Therapeutics Stock (OTCMKTS:APLIF)

Key Stats

Today's Range
$0.0108
$0.0145
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.04
Volume
357,000 shs
Average Volume
93,946 shs
Market Capitalization
$1.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

APLIF Stock Analysis - Frequently Asked Questions

Appili Therapeutics' stock was trading at $0.0280 at the beginning of 2025. Since then, APLIF stock has decreased by 50.0% and is now trading at $0.0140.
View the best growth stocks for 2025 here
.

Appili Therapeutics Inc. (OTCMKTS:APLIF) issued its earnings results on Tuesday, August, 13th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01).

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/13/2024
Today
5/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:APLIF
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.80 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$630,000.00
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-0.24

Miscellaneous

Free Float
106,908,000
Market Cap
$1.48 million
Optionable
Not Optionable
Beta
-0.51
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (OTCMKTS:APLIF) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners